Clinical Trial

Panniculitis in Dermatomyositis

Study acronym: PANNICUL
Recruiting
View on ClinicalTrials.gov →
Summary
Adipose tissue involvement is rare in dermatomyositis. The occurrence of partial or diffuse lipodystrophy is a rare but well-characterized manifestation, particularly in juvenile forms of dermatomyositis. Panniculitis, on the other hand, is exceptional and rarely described in the literature, mostly in the form of clinical cases. Panniculitis in dermatomyositis is exceptional. There are no validated diagnostic criteria or treatment recommendations. Treatment is based, by analogy, on the therapeutic strategy for lupus panniculitis and involves synthetic antimalarials combined with steroids and/or immunosuppressants. The aim of this study is to describe panniculitis in dermatomyositis in order to determine whether there are clinical or histological characteristics that distinguish it from other causes of panniculitis, particularly panniculitis associated with lupus erythematosus.
Trial Details
NCT Number NCT07345949
Lead Sponsor University Hospital, Strasbourg, France
Conditions Panniculitis, Dermatomyositis
Enrollment 20 participants
Start Date 2025-10-20
Primary Completion 2028-04 (estimated)
Study Completion 2028-04-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-16